Abstract:Proteolysis-targeting chimeras (PROTACs) are hetero-bifunctional molecules. They induce the degradation of a target protein by recruiting an E3 ligase to the target. The PROTAC can inactivate disease-related genes that are considered as understudied, thus has a great potential to be a new type of therapy for the treatment of incurable diseases. However, only hundreds of proteins have been experimentally tested if they are amenable to the PROTACs. It remains elusive what other proteins can be targeted by the PROTAC in the entire human genome. For the first time, we have developed an interpretable machine learning model PrePROTAC, which is based on a transformer-based protein sequence descriptor and random forest classification to predict genome-wide PROTAC-induced targets degradable by CRBN, one of the E3 ligases. In the benchmark studies, PrePROTAC achieved ROC-AUC of 0.81, PR-AUC of 0.84, and over 40% sensitivity at a false positive rate of 0.05, respectively. Furthermore, we developed an embedding SHapley Additive exPlanations (eSHAP) method to identify positions in the protein structure, which play key roles in the PROTAC activity. The key residues identified were consistent with our existing knowledge. We applied PrePROTAC to identify more than 600 novel understudied proteins that are potentially degradable by CRBN, and proposed PROTAC compounds for three novel drug targets associated with Alzheimer's disease. Author summary: Many human diseases remain incurable because disease-causing genes cannot by selectively and effectively targeted by small molecules. Proteolysis-targeting chimera (PROTAC), an organic compound that binds to both a target and a degradation-mediating E3 ligase, has emerged as a promising approach to selectively target disease-driving genes that are not druggable by small molecules. Nevertheless, not all of proteins can be accommodated by E3 ligases, and be effectively degraded. Knowledge on the degradability of a protein will be crucial for the design of PROTACs. However, only hundreds of proteins have been experimentally tested if they are amenable to the PROTACs. It remains elusive what other proteins can be targeted by the PROTAC in the entire human genome. In this paper, we propose an intepretable machine learning model PrePROTAC that takes advantage of powerful protein language modeling. PrePROTAC achieves high accuracy when evaluated by an external dataset which comes from different gene families from the proteins in the training data, suggesting the generalizability of PrePROTAC. We apply PrePROTAC to the human genome, and identify more than 600 understudied proteins that are potentially responsive to the PROTAC. Furthermore, we design three PROTAC compounds for novel drug targets associated with Alzheimer's disease.

TRL-PROTAC: A pre-trained generator of PROTACs targeting specific proteins optimized by reinforcement learning

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

3D based generative PROTAC linker design with reinforcement learning

DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras

A One-Pot Photocatalytic Triazole-Based Linkerology for PROTACs

PROTACable Is an Integrative Computational Pipeline of 3-D Modeling and Deep Learning To Automate the De Novo Design of PROTACs

An overview of PROTACs: a promising drug discovery paradigm

PROTAC-Design-Evaluator (PRODE): An Advanced Method for In-Silico PROTAC Design

Characteristic roadmap of linker governs the rational design of PROTACs

De novo PROTAC design using graph-based deep generative models

Elucidation of Genome-wide Understudied Proteins targeted by PROTAC-induced degradation using Interpretable Machine Learning

Rationalizing PROTAC-mediated ternary complex formation using Rosetta

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Chemistries of bifunctional PROTAC degraders

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

A close-up shot of protein-protein docking, from experiment to theory and reverse with the PROTAC performers

E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points

Integrative Modeling of PROTAC-Mediated Ternary Complexes